Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01902290 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility
A Phase 2 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 421
- Enrollment target
NCT01902290 is a Phase 2 study that was terminated before completion, run by Amgen. The registered enrollment target is 421 participants.
The verdict
NCT01902290, a Phase 2 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 421 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if brodalumab (AMG 827) is safe and effective compared to placebo as measured by change in Asthma Control Questionnaire (ACQ) composite scores.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Brodalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 421 participants |
| Start Date | 2013-05-22 |
| Est. Completion | 2015-05-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01902290
The ClinicalTrials.gov registry entry for NCT01902290 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 421 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01902290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01902290 about?
NCT01902290 is a clinical study titled "Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility". The purpose of this study is to determine if brodalumab (AMG 827) is safe and effective compared to placebo as measured by change in Asthma Control Questionnaire (ACQ) composite scores.
What is the current status of trial NCT01902290?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 421 participants. The study started on 2013-05-22. Estimated completion is 2015-05-15.
What interventions are being tested in trial NCT01902290?
The interventions under investigation include: Placebo (BIOLOGICAL), Brodalumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01902290?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.